Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy
Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spheric...
Ausführliche Beschreibung
Autor*in: |
Min Zhu [verfasserIn] Shan Wang [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Small Science - Wiley-VCH, 2021, 1(2021), 3, Seite n/a-n/a |
---|---|
Übergeordnetes Werk: |
volume:1 ; year:2021 ; number:3 ; pages:n/a-n/a |
Links: |
---|
DOI / URN: |
10.1002/smsc.202000056 |
---|
Katalog-ID: |
DOAJ006363741 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ006363741 | ||
003 | DE-627 | ||
005 | 20230309202953.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/smsc.202000056 |2 doi | |
035 | |a (DE-627)DOAJ006363741 | ||
035 | |a (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a TA401-492 | |
100 | 0 | |a Min Zhu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. | ||
650 | 4 | |a cancer therapy | |
650 | 4 | |a controlled drug release | |
650 | 4 | |a functional nucleic acids | |
650 | 4 | |a nucleic acids linking strategies | |
650 | 4 | |a spherical nanoparticles | |
650 | 4 | |a targeted drug delivery | |
653 | 0 | |a Materials of engineering and construction. Mechanics of materials | |
700 | 0 | |a Shan Wang |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Small Science |d Wiley-VCH, 2021 |g 1(2021), 3, Seite n/a-n/a |w (DE-627)1736479490 |w (DE-600)3042766-6 |x 26884046 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2021 |g number:3 |g pages:n/a-n/a |
856 | 4 | 0 | |u https://doi.org/10.1002/smsc.202000056 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1002/smsc.202000056 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2688-4046 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 1 |j 2021 |e 3 |h n/a-n/a |
author_variant |
m z mz s w sw |
---|---|
matchkey_str |
article:26884046:2021----::ucinluliaidcrtdpeiannprilsrprtosrtgeadur |
hierarchy_sort_str |
2021 |
callnumber-subject-code |
TA |
publishDate |
2021 |
allfields |
10.1002/smsc.202000056 doi (DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 DE-627 ger DE-627 rakwb eng TA401-492 Min Zhu verfasserin aut Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials Shan Wang verfasserin aut In Small Science Wiley-VCH, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1736479490 (DE-600)3042766-6 26884046 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 kostenfrei https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/toc/2688-4046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
spelling |
10.1002/smsc.202000056 doi (DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 DE-627 ger DE-627 rakwb eng TA401-492 Min Zhu verfasserin aut Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials Shan Wang verfasserin aut In Small Science Wiley-VCH, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1736479490 (DE-600)3042766-6 26884046 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 kostenfrei https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/toc/2688-4046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfields_unstemmed |
10.1002/smsc.202000056 doi (DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 DE-627 ger DE-627 rakwb eng TA401-492 Min Zhu verfasserin aut Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials Shan Wang verfasserin aut In Small Science Wiley-VCH, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1736479490 (DE-600)3042766-6 26884046 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 kostenfrei https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/toc/2688-4046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfieldsGer |
10.1002/smsc.202000056 doi (DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 DE-627 ger DE-627 rakwb eng TA401-492 Min Zhu verfasserin aut Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials Shan Wang verfasserin aut In Small Science Wiley-VCH, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1736479490 (DE-600)3042766-6 26884046 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 kostenfrei https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/toc/2688-4046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
allfieldsSound |
10.1002/smsc.202000056 doi (DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 DE-627 ger DE-627 rakwb eng TA401-492 Min Zhu verfasserin aut Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials Shan Wang verfasserin aut In Small Science Wiley-VCH, 2021 1(2021), 3, Seite n/a-n/a (DE-627)1736479490 (DE-600)3042766-6 26884046 nnns volume:1 year:2021 number:3 pages:n/a-n/a https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 kostenfrei https://doi.org/10.1002/smsc.202000056 kostenfrei https://doaj.org/toc/2688-4046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 1 2021 3 n/a-n/a |
language |
English |
source |
In Small Science 1(2021), 3, Seite n/a-n/a volume:1 year:2021 number:3 pages:n/a-n/a |
sourceStr |
In Small Science 1(2021), 3, Seite n/a-n/a volume:1 year:2021 number:3 pages:n/a-n/a |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery Materials of engineering and construction. Mechanics of materials |
isfreeaccess_bool |
true |
container_title |
Small Science |
authorswithroles_txt_mv |
Min Zhu @@aut@@ Shan Wang @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
1736479490 |
id |
DOAJ006363741 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006363741</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309202953.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/smsc.202000056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006363741</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">TA401-492</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Min Zhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">controlled drug release</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">functional nucleic acids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nucleic acids linking strategies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">spherical nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Materials of engineering and construction. Mechanics of materials</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shan Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Small Science</subfield><subfield code="d">Wiley-VCH, 2021</subfield><subfield code="g">1(2021), 3, Seite n/a-n/a</subfield><subfield code="w">(DE-627)1736479490</subfield><subfield code="w">(DE-600)3042766-6</subfield><subfield code="x">26884046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:n/a-n/a</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/smsc.202000056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/smsc.202000056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2688-4046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">n/a-n/a</subfield></datafield></record></collection>
|
callnumber-first |
T - Technology |
author |
Min Zhu |
spellingShingle |
Min Zhu misc TA401-492 misc cancer therapy misc controlled drug release misc functional nucleic acids misc nucleic acids linking strategies misc spherical nanoparticles misc targeted drug delivery misc Materials of engineering and construction. Mechanics of materials Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
authorStr |
Min Zhu |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)1736479490 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
TA401-492 |
illustrated |
Not Illustrated |
issn |
26884046 |
topic_title |
TA401-492 Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy cancer therapy controlled drug release functional nucleic acids nucleic acids linking strategies spherical nanoparticles targeted drug delivery |
topic |
misc TA401-492 misc cancer therapy misc controlled drug release misc functional nucleic acids misc nucleic acids linking strategies misc spherical nanoparticles misc targeted drug delivery misc Materials of engineering and construction. Mechanics of materials |
topic_unstemmed |
misc TA401-492 misc cancer therapy misc controlled drug release misc functional nucleic acids misc nucleic acids linking strategies misc spherical nanoparticles misc targeted drug delivery misc Materials of engineering and construction. Mechanics of materials |
topic_browse |
misc TA401-492 misc cancer therapy misc controlled drug release misc functional nucleic acids misc nucleic acids linking strategies misc spherical nanoparticles misc targeted drug delivery misc Materials of engineering and construction. Mechanics of materials |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Small Science |
hierarchy_parent_id |
1736479490 |
hierarchy_top_title |
Small Science |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)1736479490 (DE-600)3042766-6 |
title |
Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
ctrlnum |
(DE-627)DOAJ006363741 (DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9 |
title_full |
Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
author_sort |
Min Zhu |
journal |
Small Science |
journalStr |
Small Science |
callnumber-first-code |
T |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
author_browse |
Min Zhu Shan Wang |
container_volume |
1 |
class |
TA401-492 |
format_se |
Elektronische Aufsätze |
author-letter |
Min Zhu |
doi_str_mv |
10.1002/smsc.202000056 |
author2-role |
verfasserin |
title_sort |
functional nucleic‐acid‐decorated spherical nanoparticles: preparation strategies and current applications in cancer therapy |
callnumber |
TA401-492 |
title_auth |
Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
abstract |
Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. |
abstractGer |
Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. |
abstract_unstemmed |
Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
3 |
title_short |
Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy |
url |
https://doi.org/10.1002/smsc.202000056 https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9 https://doaj.org/toc/2688-4046 |
remote_bool |
true |
author2 |
Shan Wang |
author2Str |
Shan Wang |
ppnlink |
1736479490 |
callnumber-subject |
TA - General and Civil Engineering |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1002/smsc.202000056 |
callnumber-a |
TA401-492 |
up_date |
2024-07-03T20:29:49.174Z |
_version_ |
1803591183683813376 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006363741</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309202953.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/smsc.202000056</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006363741</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ80f61a28966d4a3198fc0dda970f75c9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">TA401-492</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Min Zhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Functional Nucleic‐Acid‐Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Functional nucleic acids (FNAs) have drawn widespread attention in the construction of functional nanomaterials for biomedical applications due to their inherent biological functions and sequence programmability, as well as high thermal stability and easy chemical modification. FNA‐decorated spherical nanoparticles (FSNPs) are composed of a metal/metal‐free spherical core and a radially oriented FNA shell. Attracted by their unique capabilities, such as resistance to nuclease degradation and capability of crossing the blood–brain barrier, FSNPs as smart nanomaterials for cancer therapy are reviewed. The preparation strategies of FSNPs are first summarized, and the applications of responsive linkers in stimuli‐responsive drug release are introduced. The FSNPs are categorized into aptamer‐, i‐motif‐, DNAzyme‐, antisense oligonucleotide‐, and CpG oligodeoxynucleotide‐decorated SNPs. Their applications in cancer therapy include tumor‐targeting drug delivery and controllable releasing of drugs, overcoming physiological or pathological obstacles such as blood–brain barrier and interstitial transport barriers, as well as a reversal of resistance to chemotherapy and antitumor immune response activation. The remaining challenges and future directions of FSNPs are also discussed and proposed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">controlled drug release</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">functional nucleic acids</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nucleic acids linking strategies</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">spherical nanoparticles</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted drug delivery</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Materials of engineering and construction. Mechanics of materials</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shan Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Small Science</subfield><subfield code="d">Wiley-VCH, 2021</subfield><subfield code="g">1(2021), 3, Seite n/a-n/a</subfield><subfield code="w">(DE-627)1736479490</subfield><subfield code="w">(DE-600)3042766-6</subfield><subfield code="x">26884046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:n/a-n/a</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/smsc.202000056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/80f61a28966d4a3198fc0dda970f75c9</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1002/smsc.202000056</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2688-4046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2021</subfield><subfield code="e">3</subfield><subfield code="h">n/a-n/a</subfield></datafield></record></collection>
|
score |
7.4004145 |